JPMorgan Chase & Co’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.06K | Buy |
5,103
+4,945
| +3,130% | +$2.97K | ﹤0.01% | 5595 |
|
|
2025
Q1 | $43 | Sell |
158
-37,542
| -100% | -$10.2K | ﹤0.01% | 6131 |
|
|
2024
Q4 | $19.6K | Sell |
37,700
-277,359
| -88% | -$144K | ﹤0.01% | 5224 |
|
|
2024
Q3 | $1.02M | Sell |
315,059
-37,557
| -11% | -$122K | ﹤0.01% | 3638 |
|
|
2024
Q2 | $1.06M | Buy |
352,616
+176,638
| +100% | +$530K | ﹤0.01% | 3473 |
|
|
2024
Q1 | $818K | Buy |
175,978
+157,182
| +836% | +$731K | ﹤0.01% | 3686 |
|
|
2023
Q4 | $77.8K | Buy |
18,796
+17,937
| +2,088% | +$74.3K | ﹤0.01% | 4868 |
|
|
2023
Q3 | $2.58K | Hold |
859
| – | – | ﹤0.01% | 5550 |
|
|
2023
Q2 | $2.11K | Sell |
859
-20,122
| -96% | -$49.5K | ﹤0.01% | 5422 |
|
|
2023
Q1 | $47K | Buy |
20,981
+5,478
| +35% | +$12.3K | ﹤0.01% | 4917 |
|
|
2022
Q4 | $54K | Sell |
15,503
-1,589
| -9% | -$5.54K | ﹤0.01% | 4717 |
|
|
2022
Q3 | $633K | Buy |
17,092
+1,116
| +7% | +$41.3K | ﹤0.01% | 3608 |
|
|
2022
Q2 | $304K | Buy |
15,976
+126
| +0.8% | +$2.4K | ﹤0.01% | 4128 |
|
|
2022
Q1 | $427K | Buy |
15,850
+8,426
| +113% | +$227K | ﹤0.01% | 4091 |
|
|
2021
Q4 | $167K | Sell |
7,424
-3,362
| -31% | -$75.6K | ﹤0.01% | 4623 |
|
|
2021
Q3 | $283K | Buy |
10,786
+344
| +3% | +$9.03K | ﹤0.01% | 4243 |
|
|
2021
Q2 | $334K | Buy |
10,442
+1,251
| +14% | +$40K | ﹤0.01% | 4225 |
|
|
2021
Q1 | $324K | Buy |
9,191
+1,121
| +14% | +$39.5K | ﹤0.01% | 4261 |
|
|
2020
Q4 | $259K | Buy |
8,070
+1,088
| +16% | +$34.9K | ﹤0.01% | 4066 |
|
|
2020
Q3 | $262K | Buy |
6,982
+796
| +13% | +$29.9K | ﹤0.01% | 3621 |
|
|
2020
Q2 | $277K | Buy |
+6,186
| New | +$277K | ﹤0.01% | 3539 |
|